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Abstract
Background: The purpose of this review was to summarize
the literature regarding the effects of opioids and illicit drugs
on the auditory and vestibular systems. Methods: Data were
sourced from published papers reporting hearing loss (HL)
and/or vestibular loss (VL) following misuse or overdose of
opioids or illicit drugs. Most papers consisted of retrospective single-case reports, with few retrospective reviews or
prospective cohort studies. Search terms included variations
of HL, VL, opioids, and illicit drugs. Search results yielded 51
articles published between 1976 and 2021. A total of 44 articles were reviewed after excluding studies that were not
available in English (n = 3), only described acute effects in
healthy cohorts (n = 3) or only described general health aspects in a group on methadone maintenance (n = 1). Results:
Sixteen studies reported ototoxicity from illicit drugs, 27
from prescription opioids, and 1 was unspecified. This review
shows that HL associated with amphetamines and cocaine
was typically sudden, bilateral, and temporary. HL from co-
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caine/crack and heroin often presented with greatest losses
in the mid-frequency range. HL associated with opioids was
typically sudden, bilateral, moderately severe to profound,
and in most cases permanent. The literature is sparse regarding VL from illicit drugs and opioids. Conclusion: Practitioners who see patients for sudden or rapidly progressive HL
or VL with no apparent cause should inquire about misuse of
illicit drugs and opioids, particularly when the HL does not
respond to steroid treatment.
© 2022 S. Karger AG, Basel

Introduction

Ototoxicity presents with a myriad of symptoms including hearing loss (HL), tinnitus, aural fullness, hyperacusis, imbalance, and/or vertigo. Ototoxicity is known to
result from medications used to treat conditions such as
cancer, infection, and kidney disease. Commonly recognized ototoxic medications include aminoglycoside and
macrolide antibiotics, loop diuretics, platinum-based
chemotherapeutics, antimalarials, salicylates, and nonsteroidal anti-inflammatories [e.g., D’Alonzo and Cantor, 1983; Roland and Rutka, 2004; Rybak and RamkuCorrespondence to:
Michelle L. Hughes, mhughes3 @ unl.edu

mar, 2007; Ding et al., 2016; dos Santos et al., 2020]. Accumulating case reports describe ototoxic effects resulting
from misuse of opioids and illicit drugs, yet many healthcare professionals are not aware of the audiological and
vestibular impacts of these substances. In fact, opioids
and illicit drugs have been included in some publications
listing ototoxic substances within the past decade [e.g.,
Cianfrone et al., 2011], but not included in others [e.g.,
Bisht and Bist, 2011]. Given the current opioid epidemic,
it is important for healthcare providers to understand
which of these substances can result in ototoxicity, which
otologic systems are affected (auditory and/or vestibular), and whether ototoxic effects are likely to be temporary or permanent. A more in-depth understanding of
substance misuse-related HL or vestibular loss (VL)
would guide otolaryngologists’ decisions for medical
management referrals (i.e., addiction medicine) or alternative treatment interventions for postoperative pain
control [Anne et al., 2021], particularly in patients at risk
for substance misuse.
When patients are prescribed known ototoxic medications, audiologists perform ototoxicity monitoring that
focuses on high frequencies because damage generally
manifests first at the basal end of the cochlea [e.g., Fausti
et al., 2003; Fausti et al., 2007; Konrad-Martin et al., 2014].
Vestibular function is rarely assessed as part of ototoxicity monitoring protocols [Ganesan et al., 2018]. Interestingly, opioids and illicit drugs are typically not included
as causative substances in ototoxicity training in audiology, medical school, or residency programs. Additionally,
there may be a missed opportunity to identify connections between ototoxicity and substance misuse because
healthcare providers do not generally ask patients about
the use of illicit or opioid drug use in the context of hearing or vestibular complaints, or vice versa. Specifically,
otolaryngologists may not ask questions about illicit drug
use or prescription opioid misuse for patients presenting
with sudden sensorineural HL (SSNHL) and who do not
respond to traditional steroid treatment. Conversely,
physicians who work in addiction medicine may not routinely ask questions about hearing and vestibular function. Emergency medicine physicians are often the first to
encounter patients with a drug overdose, but also do not
query about hearing or vestibular function [Kopec and
Nelson, 2012]. Thus, there is an overall disconnect in the
case history process, mediated by a lack of widespread
knowledge of the link between substance misuse and HL
or VL.
Drug overdoses are the leading cause of injury-related
death in the USA [Mack et al., 2017], with >70% in 2019
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involving opioids [CDC, 2020]. In 2019, an estimated
57.2 million Americans had used illicit drugs in the past
year, including 9.7 million who misused prescription
pain medications [SAMHSA, 2020]. There are approximately 20.4 million people in the USA who have a substance use disorder, and of the 1.6 million who have an
opioid use disorder, only 18% received medication for it
[SAMHSA, 2020]. In the USA, the opioid dispensing rate
peaked in 2012 at 81.3 prescriptions per 100 people, or
>255 million total prescriptions, excluding mail-order
prescriptions and methadone treatment [CDC, 2021].
Worldwide, an estimated 35 million people between the
ages of 15 and 65 years misuse opioids [Oroei et al., 2018].
Given the alarming public health burden of drug misuse,
there is an increased likelihood that otolaryngologists and
audiologists will encounter individuals with significant
substance misuse histories. Unfortunately, little is known
about the incidence of HL and VL in individuals who misuse illicit drugs and/or opioids. Furthermore, it is unclear
what factors lead to temporary versus permanent loss and
what underlying physiological mechanisms are responsible. Thus, the purpose of this review is to better understand from the existing literature which of these substances can result in ototoxicity, which otologic systems are
affected (auditory and/or vestibular), and whether ototoxic effects are likely to be temporary or permanent. By
gaining a more thorough understanding of these issues,
clinicians will be better equipped to query, manage, and
make appropriate referrals for individuals who present
with a history of substance misuse and be better equipped
to include detailed questions about opioid and illicit drug
use for patients who present with sudden or otherwise
unexplained HL or VL.
Methods
A literature search was conducted using PubMed and Google
Scholar without restrictions on publication dates. Search terms included combined variations of HL, deafness, VL, vestibular dysfunction, vestibular hypofunction, vestibulopathy, illicit drugs,
and opioids. Articles identified in the search results were crosschecked against relevant references within the identified papers.
Search results yielded 51 articles published between 1976 and 2021.
Three articles were excluded because they were not available in English [Mulch and Handrock, 1979; Lindeman et al., 2014; Pingarrón et al., 2014], 2 more were excluded because they examined
acute vestibular effects of fentanyl in healthy cohorts only [Rottach
et al., 2002; Ramaioli et al., 2014], and one was excluded because it
only reported general health characteristics of heroin users in a
methadone maintenance program [Du et al., 2008]. Most studies
consisted of case reports; therefore, a meta-analysis could not be
conducted. The resulting 44 studies are discussed below.
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Table 1. Summary of studies reporting illicit drugs’ and opioids’ ototoxic effects
Drug

Studies,
n

Illicit
Amphetamine
Cocaine
Cannabis
Heroin
Multi illicit
Opioids
General opioids
Opioid + acetaminophen
Methadone/propoxyphene

16*
2
2
1
7
6
27
10
7
10

Patients with
hearing loss, n

Patients with
tinnitus, n

Patients with vestibular
symptoms, n

27
2
1
8
5

2
1
–
2
5

–
0
–
2
49

34
30
21

15
23
3

28
6
2

Dashes represent information that was not reported. * Iqbal [2002b] reported findings for 3 different drugs
(amphetamines, cannabis, and heroin) in a single publication.

Results

Overview of the Literature
Of the 44 studies, 16 (37%) reported ototoxicity related to illicit drug ingestion comprised of amphetamines [Iqbal, 2002a, b], cocaine [Ciorba et al., 2009;
Stenner et al., 2009], cannabis [Iqbal, 2002b], heroin
[Polpathapee et al., 1984; Ishiyama et al., 2001; Iqbal,
2002b; Kortequee et al., 2005; Schrock et al., 2008; Antonopoulos et al., 2012; Aulet et al., 2014], or a combination of drugs [Sharma, 2001; Nicoucar et al., 2005;
Fowler and King, 2008; Nair et al., 2010; Schweitzer et
al., 2011; Moreira et al., 2012]. One additional study
[Józefowicz-Korczynska et al., 1994] reported vestibular and audiometric results for people addicted to
“drugs” that were not specified beyond noting inclusion
of opiates, barbiturates, and inhalants. The remaining
27 studies (61%) reported ototoxicity from prescription
of opioids including morphine, oxymorphone, hydrocodone, oxycodone [Kurnatowski and Garganisz, 1996;
Ho et al., 2007; Rawool and Dluhy, 2011; Kopec and
Nelson, 2012; Boyle and Rosenbaum, 2013; Helander et
al., 2014; MacDonald et al., 2015; Leache et al., 2016;
Ntranos et al., 2017; Mozeika et al., 2020], the combination of an opioid (hydrocodone, codeine, oxycodone, or
dextropropoxyphene) and acetaminophen [Ramsay,
1991; Friedman et al., 2000; Oh et al., 2000; Blakley and
Schilling, 2008; Rigby and Parnes, 2008; Freeman et al.,
2009; Novac et al., 2015], and maintenance medications
that included methadone or propoxyphene [Lupin and
Harley, 1976; Harell et al., 1978; van Gaalen et al., 2009;
Christenson and Marjala, 2010; Shaw et al., 2011; VoraHearing and Vestibular Loss with Drug
Misuse

subin et al., 2013; Bayat et al., 2019; Ghasemi et al., 2019;
Repple et al., 2021].
Substance types are summarized in Table 1, along with
the total number of patients reporting either HL or VL.
Most publications (35/44 or 79.5%) were case reports of
1–9 patients. Of the remaining 9 studies (20%) involving
larger cohorts, 2 reported results for use of illicit drugs
[Iqbal, 2002b; Moreira et al., 2012], 6 reported on misuse
of prescription opioids [Kurnatowski and Garganisz,
1996; Friedman et al., 2000; Freeman et al., 2009; Rawool
and Dluhy, 2011; Bayat et al., 2019; Mozeika et al., 2020],
and 1 reported on “drugs” that included both opioids and
illicit substances [Józefowicz-Korczynska et al., 1994].
Results from Józefowicz-Korczynska et al. [1994] are not
included in Table 1 because data for all substances were
reported in aggregate. The results of these studies are discussed in the following sections, categorized by either illicit drugs or prescription opioids. Figure 1 summarizes
all reports of HL (Fig. 1a) and VL (Fig. 1b) across 43 of
the 44 studies by substance type, excluding the data from
Jozefowicz-Korczynska et al. [1994]. In all cases, HL was
either documented as or presumed to be sensorineural in
nature.
Illicit Drugs
For amphetamines, 2 studies on a total of 27 men reported HL that was sudden, bilateral, and temporary in
all cases [Iqbal, 2002a, b]. Hearing recovered within a few
days to up to 10 days. HL and subsequent resolution were
self-report only and not verified audiometrically; therefore, it is unclear whether any residual high-frequency HL
remained. The degree of HL was not specified, and vesAudiol Neurotol 2022;27:271–281
DOI: 10.1159/000521965
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tibular results were not reported. Proposed mechanisms
for the HL were transient temporal lobe ischemia or
changes in neural signaling through depletion of neurotransmitters.
For the 2 case studies involving cocaine, the HL was
sudden, moderate to severe, bilateral, and temporary, resolving within 3 days [Stenner et al., 2009] to 1 month
[Ciorba et al., 2009]. In both cases, the patients denied
274
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vestibular symptoms. Crack/cocaine can cause permanent damage to neural structures including myelin and
neurotransmitters [Weich et al., 2012]; however, this
would not explain the transient nature of the HL. Ciorba
et al. [2009] proposed the HL was potentially due to a disruption in the endocochlear potential because cocaine is
a fast K+ channel blocker.
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For the 7 case studies involving heroin, all 8 patients
presented with SSNHL ranging from moderately severe
to profound HL [Polpathapee et al., 1984; Ishiyama et al.,
2001; Iqbal, 2002b; Kortequee et al., 2005; Schrock et al.,
2008; Antonopoulos et al., 2012; Aulet et al., 2014]. HL
was bilateral for all but 1 patient who had injected heroin
into his neck, in which case the profound permanent HL
was on the side injected [Kortequee et al., 2005]. Hearing
fully recovered for 4 patients, partially recovered for 2,
and did not improve for 2. Tinnitus was reported for 2
patients, denied for 2 patients, and not reported for the
rest. Two patients presented with vestibular symptoms,
both of which resolved [Ishiyama et al., 2001; Kortequee
et al., 2005]. Interestingly, in 4 cases, patients had chronically used heroin, went through a period of abstinence,
and then relapsed with an overdose resulting in the
SSNHL [Polpathapee et al., 1984; Ishiyama et al., 2001;
Schrock et al., 2008; Antonopoulos et al., 2012]. HL was
temporary for 2 of those patients, partially recovered for
1, and permanent for 1.
It is unclear what mechanisms contribute to heroininduced HL. Proposed etiologies include changes in sensitivity to opioid receptors in the cochlea [Ishiyama et al.,
2001], cochlear and central auditory damage [Polpathapee et al., 1984], or ototoxic additives to heroin such as

quinine, which can cause temporary HL [Schrock et al.,
2008; Antonopoulos et al., 2012; Aulet et al., 2014]. Antonopoulos et al. [2012] reported a mild sloping to moderately severe SNHL in a patient who had overdosed on
heroin. Otoacoustic emissions were absent, as would be
expected for this degree of HL; however, auditory brainstem responses were also absent at 105 dB nHL suggesting
both cochlear and retrocochlear effects. Only one study
reported HL with cannabis use [Iqbal, 2002b], which was
bilateral, sudden, and temporary, with no report regarding vestibular function or degree of HL.
Six studies reported misuse of multiple combined illicit drugs. Five were single-case studies involving combinations of cocaine/crack and either heroin or methadone
[Nicoucar et al., 2005; Fowler and King, 2008; Nair et al.,
2010], heroin and benzodiazepines [Schweitzer et al.,
2011], or ecstasy (also known as MDMA, an amphetamine derivative similar to methamphetamine that is
combined with a hallucinogen) with methadone [Sharma, 2001]. All patients in these single-case studies experienced SSNHL, with the majority experiencing bilateral
loss (4/5), and tinnitus (5/5). The degree of HL ranged
from mild-moderate to profound. HL was permanent for
most (4/5), despite some improvement in 3 of those patients, whereas it was unknown whether hearing recovered in 1 case [Fowler and King, 2008]. In the 1 case with
unilateral SSNHL [Nicoucar et al., 2005], ingestion was
intranasal resulting in a permanent SNHL due to an intralabyrinthine hemorrhage found on magnetic resonance imaging. Of the 5 cases, 2 patients reported dizziness [Sharma et al., 2001; Nicoucar et al., 2005], 1 patient
denied vestibular symptoms [Schweitzer et al., 2011], and
the remaining cases did not report on vestibular function
[Fowler and King, 2008; Nair et al., 2010]. Only one cohort study for various illicit drugs [Moreira et al., 2012]
has reported objective vestibular testing. In a group of 47
people who used marijuana and/or cocaine/crack with alcohol compared to a healthy control group of 47 people,
Moreira et al. [2012] utilized computerized electronystagmography to measure pendular tracking, optokinetic,
and spontaneous, positional, and positioning nystagmus.
A pendular rotary and caloric test was included with
stimuli not described. Functional balance was measured
using a dynamic posturography unit. Of the 47 users of
illicit drugs, 46 reported vestibular symptoms, but 43 had
normal findings, whereas 4 had reduced caloric responses consistent with peripheral dysfunction. However,
overall mean sway on posturography and for visual-vestibular specific test conditions showed lower balance stability for the group of illicit drug users when compared to
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Fig. 2. Mean (±1 SD) audiometric thresholds for 19 ears in 10 patients (1 with unilateral HL) resulting from misuse of cocaine/
crack and/or heroin.
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the control group, suggestive to the authors that illicit
drugs disrupt central pathway integration of visual, vestibular, and visual-vestibular stimuli. Audiometric results
were not reported in that study.
Of the 16 studies involving illicit drugs, 11 had published patient audiograms. Ten of these were for cocaine/
crack and/or heroin. One interesting observation emerged
among this group, which has not been reported previously. Many patients presented with cookie-bite audiograms (mid-frequency SNHL, or MFSNHL), with the
maximum HL occurring between 1 and 4 kHz. Figure 2
shows the mean (±1 SD) audiometric thresholds estimated from the published audiograms for 19 ears in 10 patients (1 had unilateral HL). This pattern conflicts with
traditional ototoxicity-induced HL where the highest frequencies are affected first, suggesting that the mechanisms involved differ from those that cause HL for common ototoxic medications. MFSNHL is uncommon, accounting for <1% of all HL patterns [Shah et al., 2005] and
5% of all SSNHL [Young, 2020]. MFSNHL is most often
attributed to genetic non-syndromic etiologies [Martini
et al., 1997; Shah et al., 2005; Xia et al., 2016; Yamamoto
et al., 2017], with approximately 22% of cases attributed
to small vestibular schwannomas [Saunders et al., 1995].
Of the 10 patients represented in Figure 2, word recognition scores were reported for 4 of them [Polpathapee et
al., 1984; Nair et al., 2010; Schweitzer et al., 2011; Aulet et
al., 2014]. In all 4 cases, scores were symmetrical between
ears and ranged from 4% [Aulet et al., 2014] to 80% [Schweitzer et al., 2011].
Prescription Opioids
Of the 27 studies reporting ototoxicity following misuse of prescription opioids, 16 reported on single cases, 5
reported on a series of cases (2–9 patients), and 6 reported on cohorts of 10 or larger. Across the 21 studies reporting on single or multiple individual cases involving opioids, HL was temporary for 11 individuals and permanent for 20, with the largest percentage of permanent HL
occurring for individuals who had misused opioid-acetaminophen combinations (100%). In most cases, HL secondary to opioid misuse presented with a sudden or rapidly progressive onset, and steroid treatment was usually
ineffective [Oh et al., 2000].
Mozeika et al. [2020] published the most comprehensive and largest study to date focusing on HL with opioid
misuse. Data were collected from 2 decades of information contained in New Jersey’s statewide poison center
database. Of 41 individuals presenting with hearing complaints time locked with opioid use, 29% became deaf,
276
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36% sustained HL, 24% experienced tinnitus, and 10%
reported a combination of some degree of HL and tinnitus. However, it did not appear that audiograms were
completed, as “auditory dysfunction” was based on subjective reports in the medical record. In all but 1 case, HL
occurred bilaterally. Of these 41 individuals, there were
additional outcomes on only 19 at the time of hospital
discharge. HL was reported as completely resolved for 7
individuals, partially resolved for 8, and unresolved for 4.
Again, it was unclear whether these results were based on
audiometric testing or subjective reports. Vestibular
function was not addressed in the study.
Rawool and Dluhy [2011] reported on the incidence of
HL in 23 men who used unspecified opioids with or without a history of noise exposure. Of this group, only 4 did
not have a history of either hobby or occupational noise
exposure, and 2 of those had HL. Vestibular function was
not addressed. Bayat et al. [2019] reported permanent bilateral HL in a group of 11 of 27 men in a treatment program undergoing methadone maintenance. HL onset
(sudden vs. progressive), degree, and vestibular function
were not reported.
Friedman et al. [2000] reported on 12 patients with
permanent profound SNHL stemming from a hydrocodone-acetaminophen combination. In all cases, HL was
sudden or rapidly progressive and was bilateral for 8/12
patients. Only 2 patients reported vestibular symptoms at
the time of the HL. Eight patients subsequently received
cochlear implants (CIs). Neither dosage nor duration of
use reportedly predicted the degree of HL at onset, rate of
progression (sudden vs. rapidly progressive), or symmetry.
Freeman et al. [2009] reported on 10 individuals who
took excessive amounts of codeine and acetaminophen
resulting in bilateral profound deafness leading to subsequent cochlear implantation. Notably, all patients presented with their highest mean corpuscular volume at a
time that coincided with their sudden or rapidly progressive HL. Given the microvascular structures within the
cochlea, the authors speculated that the HL may have resulted from a vascular pathology. Despite the rapid progression of severe/profound HL, 9/10 patients denied
vestibular symptoms, and all had normal vestibular test
results, which aligns with the greater sensitivity of the cochlea to vascular flow than the vestibule.
Across all studies involving prescription opioids, 28 of
67 people (42%) who sustained permanent HL received
CIs. CIs have been shown to work well for those who experienced permanent severe-profound HL secondary to
opioid use, so the locus is presumed to be cochlear [Ho et
Hughes/Rodriguez/Hatch/Zoucha

al., 2007; Blakley and Schilling, 2008; Freeman et al.,
2009]. The underlying cause of opioid-induced HL, however, is not known. Potential mechanisms have been proposed, including ischemic damage, hypoxic changes
within the cochlea, genetic variations in metabolic processes, or effects on homeostasis such as a disruption of
the endocochlear potential [Kopec and Nelson, 2012; Saifan et al., 2013; Oroei et al., 2018; Bayat et al., 2019]. Given the heterogeneity of onset, degree, and symmetry
among cases, individual differences could be mediated by
type of substance(s) used, age, gender, route of ingestion
(e.g., oral, injected, inhaled), genetic and metabolic factors, and comorbid medical conditions such as cardiac or
renal failure [Ganesan et al., 2018]. As noted earlier, however, Freeman et al. [2009] found that neither dosage nor
duration of use appeared to predict onset, degree, or symmetry.
Using mouse models, Yorgason et al. [2010] found
that acetaminophen – rather than hydrocodone – is the
primary ototoxic agent in Vicodin® (Knoll Labs, Mt. Olive, NJ, USA), with HL resulting primarily from oxidative
and endoplasmic reticulum stress [Kalinec et al., 2014].
Yorgason et al. [2010] also stated that acetaminophen
ototoxicity was potentiated by hydrocodone and suggested acetaminophen may work synergistically with hydrocodone to damage auditory cells. These findings contradict earlier sources noting no published reports of ototoxicity resulting strictly from acetaminophen [LonsburyMartin and Martin, 2007]. However, HL has resulted
from many different types of opioids (unpaired with acetaminophen), which may implicate compromised function of opioid receptors in the cochlea [Ishiyama et al.,
2001; Kopec and Nelson, 2012; Mozeika et al., 2020], as
all 3 opioid receptors are found in the human cochlea. In
many of the single case studies, vestibular symptoms were
less documented as compared to auditory effects, suggesting potential differential effects of opioid use on the
auditory and vestibular systems. However, vestibular
function results were not always published or information on the assessments used was minimal.
One large-cohort study [Józefowicz-Korczynska et al.,
1994] involving 96 males aged 15–35 years addicted to
“drugs” reported HL in 112 ears in 62 (65%) patients.
Comprehensive vestibular testing revealed an abnormal
caloric finding (e.g., high directional preponderance, reduced total beats of nystagmus, caloric weakness) for 88
(92%) patients. Overall, electronystagmography with caloric results indicated peripheral vestibular involvement
for 20 (25%) individuals and central involvement for 59
(61%). Results were not considered in the context of sub-

stance type, other than a statement noting that substances such as opiates, barbiturates, and inhalants were used.
Therefore, it is unclear which substances were associated
with HL or VL.
Finally, a large cohort study [Kurnatowski and Garganisz, 1996] involving 62 adults (predominately men)
who had past unspecified opioid misuse and in treatment and 50 healthy volunteers received comprehensive vestibular testing using electronystagmography.
Within the group with past opioid use, 24 reported vestibular symptoms, 12 (19%) had peripheral vestibular
dysfunction (e.g., caloric weakness, horizontal positional nystagmus), and 43 (69%) had signs of central vestibular dysfunction (e.g., poor ocular motility, cerebellar signs), with overall significant vestibular outcome
differences when compared to the healthy volunteer
group. Objective hearing outcomes were not obtained
in this study.
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Limitations
Several limitations in the current literature make it difficult to fully understand the incidence and impacts of
substance misuse on the inner ear. First, most studies relied on self-reports of HL. Approximately half of the studies that reported HL secondary to substance use either did
not obtain audiometric results, or if they did have testing
done, the results were not published. It is therefore unclear whether the nature of the HL was sensorineural, as
they were presumed. It is also unclear what the degree of
HL was, as some case studies solely reported that patients
stated they “couldn’t hear.”
Second, it is unclear in cases reporting recovery of HL
whether the hearing fully recovered. All studies were retrospective, so there were no baseline audiograms prior to
substance use or prior to the complaint of HL. Additionally, it is more common for people to be unaware of the
presence of high-frequency HL. Because ototoxicity typically begins with damage to the basal end of the cochlea,
it is possible that patients had residual high-frequency HL
in cases where HL reportedly recovered.
Third, vestibular symptoms were not reported in half
(22 of 44) of the studies. In most of the studies that reported normal vestibular function, approximately 50%
did not report formal results from clinical vestibular assessments. Even when results were provided, assessments
were either specific to only the semicircular canal (whereas other vestibular end-organ deficits are possible) or only
included a measure of balance, which cannot isolate the
inner ear. Due to the proximity of the cochlea and vestibule, along with the similarity of some of the structures,
277

it is possible that substances might affect both the hearing
and vestibular systems with different severities. Notably,
research suggests that individuals with SNHL often have
concomitant saccular dysfunction in the same ear. The
mechanisms proposed are the cochlea and saccule’s common embryologic origin in the pars inferior of the labyrinth, noise exposure effects, and/or ischemic changes
given that the cochlea and saccule share a common arterial supply [Zuniga et al., 2012]. However, because the
peripheral vestibular pathology can compensate at the
level of the cerebellar vestibular nuclei, it is possible that
VL could still exist in patients without being functionally
noticed until the loss has progressed. Without more objective and comprehensive vestibular testing, the true
prevalence of VL associated with substance misuse is likely underreported.
Fourth, it is unclear how the incidence of SSNHL in
people who misuse substances – particularly in cases of
overdose – differs from that of the general population. In
a large cross-sectional study examining data from over 60
million insured patients, Alexander and Harris [2013] reported the incidence of idiopathic SSNHL was 27 per
10,000 per year for data spanning 2006–2007. This number included both inpatient and outpatient claims. The
etiology of SSNHL is unknown in approximately 70% of
cases [Chau et al., 2010]. To focus on the unknown etiologies, the study excluded individuals with concomitant
diagnoses that were associated with known SSNHL such
as Meniere’s disease, vestibular schwannoma, labyrinthine fistula, noise-induced HL, and congenital HL. They
found the incidence of SSNHL increased with age, and
men were slightly more likely than women to experience
SSNHL. The authors theorized these age and gender
trends might be attributed to the increased risk of vascular events in men and in the elderly. One limitation of the
study is that the data were obtained through a medical
and pharmaceutical claims database, and therefore did
not capture health conditions in uninsured people. This
is important because illicit drug use increases the risk of
being uninsured [Wang and Xie, 2017]. Additionally, it is
unclear the extent to which their data captured individuals who misuse substances, as other codes related to addiction or overdose were not considered. The incidence
of SSNHL in people who misuse illicit drugs and prescription opioids is unclear.
Last, the type of substances used was typically self-reported, although toxicology tests were run in some cases.
In cases where multiple substances were used, it is difficult to know which were involved in causing hearing or
vestibular dysfunction. Furthermore, it is known that il278
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licit drugs can contain impurities such as quinine, metals,
or organic solvents [Iqbal, 2002a; Antonopoulos et al.,
2012], which also can be ototoxic.
Implications for Clinical Practice
A multidisciplinary approach is recommended when
patients present with hearing or vestibular complaints –
especially of sudden onset – coupled with a positive history of substance misuse. For many of the case reports
presented here, patients were first evaluated in the emergency department. These patients might be seen by otolaryngology during admission or for follow-up after discharge. This review shows that HL associated with amphetamines and cocaine was typically sudden, bilateral,
and temporary. HL associated with opioids was usually
sudden, bilateral, moderately severe to profound, and in
most cases, permanent. Therefore, otologists and otolaryngologists who see patients for sudden or rapidly progressive HL or VL with no apparent cause should inquire
about misuse of illicit drugs and opioids, particularly
when the HL does not respond to steroid treatment. If a
patient’s history is positive for substance misuse, a referral should be made to addiction medicine for further
management, regardless of whether the HL resolves.
Likewise, practitioners working in pain or addiction
medicine, methadone maintenance clinics, or other treatment centers should include screening questions about
HL, tinnitus, aural fullness, and dizziness that may warrant audiological or otologic referral.
Certain groups who are at risk for HL are also at higher risk for opioid misuse, such as military veterans, older
adults, and workers in manual-labor jobs [Rigg and Rigg,
2020]. These groups have a high rate of being prescribed
opioids for pain management. Additionally, veterans are
at higher risk for noise-induced HL, older adults are at
higher risk for age-related HL, and manual-labor workers
are at higher risk for exposure to hazardous noise and
ototoxic agents [Rigg and Rigg, 2020]. Therefore, detailed
case histories should identify individuals who have a high
risk of age- or noise-related HL and potential for opioid
misuse.
It is unclear how much healthcare providers know
about ototoxicity effects secondary to illicit drug use or
misuse of prescribed opioids. Many of the publications
covered in this review noted that HL is a rare adverse effect associated with illicit drug use. However, in 2007, Ho
et al. [2007] described opioid-induced ototoxicity as “infrequently recognized,” whereas more recently, Mozeika
et al. [2020] described it as “a known complication.” Thus,
there is a need for increased awareness of illicit- and opiHughes/Rodriguez/Hatch/Zoucha

oid-induced ototoxicity across disciplines spanning otolaryngology, audiology, pain, addiction, and emergency
medicine.
Conclusion

Although the number of reports of HL and/or VL secondary to misuse of illicit drugs and opioids has increased
over the past 2 decades, systematic research regarding
prevalence and outcomes is lacking. Practitioners who see
patients for unexplained sudden or rapidly progressive
HL or VL should inquire about misuse of illicit drugs and
opioids, especially if steroid treatment is not effective.
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